Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.65 and traded as high as $3.44. Anavex Life Sciences shares last traded at $3.39, with a volume of 666,861 shares traded.
Wall Street Analysts Forecast Growth
AVXL has been the subject of a number of analyst reports. Rodman & Renshaw assumed coverage on Anavex Life Sciences in a research report on Monday, May 4th. They set a "buy" rating and a $20.00 price objective for the company. Weiss Ratings downgraded Anavex Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Anavex Life Sciences currently has an average rating of "Hold" and an average target price of $21.33.
Read Our Latest Report on Anavex Life Sciences
Anavex Life Sciences Trading Up 1.5%
The firm has a market capitalization of $314.15 million, a P/E ratio of -8.69 and a beta of 1.15. The business's 50 day simple moving average is $2.65 and its two-hundred day simple moving average is $3.37.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its earnings results on Thursday, July 30th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Analysts predict that Anavex Life Sciences Corp. will post -0.33 EPS for the current fiscal year.
Hedge Funds Weigh In On Anavex Life Sciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVXL. State of Wyoming bought a new stake in shares of Anavex Life Sciences in the 2nd quarter worth $26,000. Quarry LP bought a new position in shares of Anavex Life Sciences during the third quarter valued at $36,000. HBW Advisory Services LLC bought a new position in shares of Anavex Life Sciences during the fourth quarter valued at $40,000. Advisory Alpha LLC purchased a new stake in shares of Anavex Life Sciences during the fourth quarter valued at $44,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Anavex Life Sciences during the fourth quarter valued at $44,000. 31.55% of the stock is owned by institutional investors.
Anavex Life Sciences Company Profile
(
Get Free Report)
Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.
The company's lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer's disease and Parkinson's disease dementia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
